

## Cinacalcet 치료 시 초기반응의 중요성

한림대학교 의과대학<sup>1</sup>, 고려대학교 의과대학<sup>2</sup>, 전남대학교 의과대학<sup>3</sup>, 인제대학교 의과대학<sup>4</sup>  
가톨릭대학교 의과대학<sup>5</sup>, 이화여자대학교 의과대학<sup>6</sup>, 순천향대학교 의과대학<sup>7</sup>, 연세대학교 의과대학<sup>8</sup>

김좌경<sup>1</sup>, 권영주<sup>2</sup>, 김수완<sup>3</sup>, 김영훈<sup>4</sup>, 박철휘<sup>5</sup>, 최규복<sup>6</sup>, 황승덕<sup>7</sup>, 최규현<sup>8</sup>

### Early Response to Cinacalcet Could Predict Subsequent Clinical Outcomes: A Prospective, Multi-center Study in Hemodialysis

### Early Response to Cinacalcet Could Predict Subsequent Clinical Outcomes

Jwa Kyung Kim<sup>1</sup>, Young Joo Kwon<sup>2</sup>, Soo Wan Kim<sup>3</sup>, Yeong Hoon Kim<sup>4</sup>  
Cheol Whee Park<sup>5</sup>, Kyu Bok Choi<sup>6</sup>, Seung Duk Hwang<sup>7</sup>, Kyu Hun Choi<sup>8</sup>

Hallym University College of Medicine<sup>1</sup>, Korea University College of Medicine<sup>2</sup>  
Chonnam National University Medical School<sup>3</sup>, Inje University College of Medicine<sup>4</sup>  
Catholic University College of Medicine<sup>5</sup>, Ewha Woman's University College of Medicine<sup>6</sup>  
Soonchunhyang University College of Medicine<sup>7</sup>, Yonsei University College of Medicine<sup>8</sup>

**Aims:** Cinacalcet is effective in treating refractory secondary hyperparathyroidism (SHPT), but little is known about the response rates and clinical factors influencing its therapeutic response.

**Materials and Method:** This study was a prospective, open-label, single-arm, multi-center study consisting of a 4-week pretreatment and 24-week treatment period. There was no upper limit of the serum intact parathyroid hormone (iPTH) level for enrollment, and cinacalcet was started at a dose of 25 mg daily and titrated to achieve a serum iPTH level <300 pg/mL (primary end point).

**Results:** Fifty-seven patients were examined (mean age: 50.9 years; dialysis duration: 11.1 years). Based on the magnitude of iPTH decrease, patients were divided into responder (n=47, 82.5%) and non-responder (n=10, 17.5%) groups. Among those in the responder group, 38 achieved the primary end point, and 9 patients showed a reduction in serum iPTH of 30% or more but did not reach the primary end point. Patients who did not respond to cinacalcet were significantly younger ( $p=0.026$ ), male ( $p=0.041$ ), and non-diabetic ( $p<0.001$ ), compared to responders. Among responders, an early response (defined as a decrease of iPTH more than 50% within 1 month) was observed in 30/47 (63.8%) patients, of whom the majority (27/30, 90.0%) achieved the primary end point. Multivariate analysis showed that early response (OR 21.54, CI 2.94–157.7) was a significant factor affecting achievement of iPTH target.

**Conclusions:** Cinacalcet was effective in hemodialysis patients with SHPT. The presence of an early response was closely associated with a favorable reduction in iPTH levels.

**Key Words:** 시나칼셋, 혈액투석, 부갑상선 호르몬

Cinacalcet, Hemodialysis, Parathyroid hormone